SISRAM MED (01696) announced that the group maintained strong growth momentum in new orders during the third quarter of 2025, driven primarily by performance in China, South Korea, and Thailand markets. Its multifunctional flagship device, Alma Harmony, achieved steady growth this quarter. As a result, the group reported unaudited double-digit year-on-year revenue growth for the period.

Leveraging continuous market expansion and demand exploration, the group will further enhance the penetration of its Soprano series in the Asia-Pacific region this year and fully advance the commercial deployment of Universkin by Alma in the U.S. market. Meanwhile, it will proceed as planned with the orderly commercialization of DaxiFacial in Mainland China.